We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Epilepsy Surgery Demonstrates Long Term Positive Results

By HospiMedica International staff writers
Posted on 25 Oct 2011
A new study has found that neurosurgery for refractory focal epilepsy leaves half of the adults treated free of seizures for up to 10 years.

Researchers at University College London (UCL; United Kingdom) conducted a prospective cohort study of the long-term outcome of surgery for epilepsy in 615 adults (497 anterior temporal resections, 40 temporal lesionectomies, 40 extratemporal lesionectomies, 20 extratemporal resections, 11 hemispherectomies, and seven palliative procedures), with prospective annual follow-up for a median of eight years. More...
The researchers used Kaplan-Meier survival analysis to estimate time to first seizure, and investigated patterns of seizure outcome.

The results showed that an estimated 52% of patients remained seizure free--apart from simple partial seizures (SPS)--at five years after surgery, and 47% at 10 years. Patients who had extratemporal resections were more likely to have seizure recurrence than were those who had anterior temporal resections, whereas for those having lesionectomies, no difference from anterior lobe resection was recorded. Those with SPS in the first two years after temporal lobe surgery had a greater chance of subsequent seizures with impaired awareness than did those with no SPS. Relapse was less likely the longer a person was seizure free and, conversely, remission was less likely the longer seizures continued. The study was published in the October 15, 2011, issue of the Lancet.

“Neurosurgical treatment is appealing for selected people with refractory focal epilepsy,” concluded senior author John Duncan, MD, and colleagues of the UCL Institute of Neurology. “Our data provide realistic expectations and indicate the scope for further improvements in presurgical assessment and surgical treatment of people with chronic epilepsy.”

First line therapy for epilepsy involves treatment with anticonvulsive drugs, and most patients will respond to one or two different medication trials. However, in up to one third of patients with epilepsy, medication alone fails to eliminate seizures, and can also cause unacceptable adverse effects. In these patients, workup for the feasibility of epilepsy surgery should be considered, using a neurosurgical procedure in which the focal area of the brain involved in the seizures is either resected, disconnected, or is stimulated. The goal is to eliminate seizures or significantly reduce seizure burden.

Related Links:
University College London


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.